Compare HSBC Holdings plc (HSBC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Vertex Pharmaceuticals Incorporated — how do they compare? HSBC Holdings plc trades at $103.84 (market cap $353.82B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: HSBC Holdings plc is far larger — about 2.6× Vertex Pharmaceuticals Incorporated's market cap, and HSBC Holdings plc pays a 3.63% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| HSBC | VRTX | |
|---|---|---|
Market Cap | $353.82B | $134.25B |
Sector | Technology | Health |
52-Week High | $107.86 | $529.65 |
52-Week Low | $63.84 | $376.62 |
Dividend Yield | 3.63% | — |
Enterprise Value | — | $128.37B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
